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Abstract
Background: The role of cyclooxygenase(COX)-1 and COX-2 in the saluretic and renin-angiotensin responses to loop
diuretics in the cat is unknown. We propose in vivo characterisation of isoform roles in a furosemide model
by administering non-steroidal anti-inflammatory drugs (NSAIDs) with differing selectivity profiles: robenacoxib
(COX-2 selective) and ketoprofen (COX-1 selective).
Results: In this four period crossover study, we compared the effect of four treatments: placebo, robenacoxib
once or twice daily and ketoprofen once daily concomitantly with furosemide in seven healthy cats. For each
period, urine and blood samples were collected at baseline and within 48 h of treatment starting. Plasma renin activity
(PRA), plasma and urinary aldosterone concentrations, glomerular filtration rate (GFR) and 24 h urinary volumes,
electrolytes and eicosanoids (PGE2, 6-keto-PGF1α, TxB2), renal injury biomarker excretions [N-acetyl-beta-D-glucosaminidase
(NAG) and Gamma-Glutamyltransferase] were measured. Urine volume (24 h) and urinary sodium, chloride and calcium
excretions increased from baseline with all treatments. Plasma creatinine increased with all treatments except placebo,
whereas GFR was significantly decreased from baseline only with ketoprofen. PRA increased significantly with placebo
and once daily robenacoxib and the increase was significantly higher with placebo compared to ketoprofen (10.5 ± 4.4
vs 4.9 ± 5.0 ng ml−1 h−1). Urinary aldosterone excretion increased with all treatments but this increase was inhibited by
75 % with ketoprofen and 65 % with once daily robenacoxib compared to placebo. Urinary PGE2 excretion decreased
with all treatments and excretion was significantly lower with ketoprofen compared to placebo. Urinary TxB2
excretion was significantly increased from baseline only with placebo. NAG increased from baseline with all
treatments. Immunohistochemistry on post-mortem renal specimens, obtained from a different group of cats that died
naturally of non-renal causes, suggested constitutive COX-1 and COX-2 co-localization in many renal structures including
the macula densa (MD).
Conclusions: These data suggest that both COX-1 and COX-2 could generate the signal from the MD to the renin
secreting cells in cats exposed to furosemide. Co-localization of COX isoenzymes in MD cells supports the functional
data reported here.
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Background
The COXibs are a class of non-steroidal anti-inflammatory
drugs (NSAIDs) which selectively inhibit cyclooxygenase
(COX)-2, whilst sparing COX-1 activity. They were devel-
oped to provide analgesic and anti-inflammatory actions
with greater safety than conventional NSAIDs, which are
usually non-selective inhibitors [1]. Nevertheless, concerns
over the renal safety COXibs have been raised [2]. Indeed,
acute kidney injury, marked sodium retention and exacer-
bation of systemic hypertension have been reported with
the use of COX-2 selective drugs in humans [2, 3].
COX isoforms exert key roles in the regulation of renal
function through the production of protective prostaglan-
dins (prostaglandin (PG)E2 and prostacyclin) [2, 4]. COX-1
is expressed in several renal cell types and is respon-
sible for maintaining renal blood flow by attenuating
vasoconstriction of the afferent arteriole (mediated by
angiotensin II) through PGE2 or prostacyclin released
locally [5]. Therefore, COX-1 inhibition by NSAIDs may
precipitate ischaemic renal injury and decrease glomerular
filtration rate (GFR) in hypovolaemic patients.
In several species COX-2 is constitutively expressed in a
limited number of kidney cell types: the macula densa
(MD) and cortical thick ascending loop and medullary
interstitial cells [6, 7]. The degree of renal COX-2 expres-
sion varies with age and disease state [6, 8, 9], when renal
homeostasis may become “prostaglandin dependent”. Re-
stricted COX-2 expression suggests differing functional
roles in the cortex and medulla. Indeed, prostanoids de-
rived from medullary COX are essential in promoting
natriuresis [10], whereas cortical COX regulates renin re-
lease, which maintains GFR despite fluctuations in sys-
temic arterial blood pressure [11]. Moreover, activation of
the renin angiotensin aldosterone system (RAAS) stabilises
arterial blood pressure and blood volume through vaso-
constriction and increases sodium and water retention.
The reliance of renin release on COX-2 was demon-
strated healthy human volunteers given furosemide (high
renin state model) together with celecoxib (COX-2 select-
ive) or indomethacin (non-selective) [12]. We do not
know much about effects of COX inhibition in the feline
kidney or the role of each isoenzyme in mediating natri-
uresis and RAAS activation or on the localisation of COX
expression in cats with normal kidney function. Such in-
formation has clinical safety implications, as NSAIDs are
used to treat pain in cats of all ages with normal or de-
creased plasma volume.
The aim of the present study was to elucidate localisa-
tion of COX-1 and COX-2 and identify their roles in
stimulating renin secretion, secondary to a furosemide
challenge in healthy cats. Of NSAIDs licensed for cats, two
have differing COX-isoenzyme selectivities: robenacoxib (1
to 2 mg kg−1 oral, once daily) is a selective COX-2 inhibi-
tor [13], whereas ketoprofen (1 mg kg−1 oral, once daily) is
a selective COX-1 inhibitor [13, 14]. The study objectives
were: (1) to determine the effects of COX-2 (robenacoxib)
and COX-1 (ketoprofen) inhibition on furosemide-induced
changes in the healthy cats, namely (i) diuretic and salure-
tic responses, (ii) GFR regulation, (iii) RAAS activation and
(iv) possible nephrotoxicity; (2) to identify COX-1 and
COX-2 immunolocalization in kidneys from cats with nor-
mal renal function.
Results
In vivo furosemide study
The mean doses of robenacoxib were 1.6 mg kg−1 d−1
for once daily dosing (range = 1.38–1.74) and 3.2 mg kg
−1 d−1 for dosing twice daily dosing( range = 2.76–
3.36 mg kg−1 d−1).
Diuresis and natriuresis
Twenty-four hour-corrected urine volumes were signifi-
cantly increased from baseline with all treatments, by 139,
94, 88 and 80 % with placebo, once daily robenacoxib, twice
daily robenacoxib and ketoprofen, respectively (Fig. 1a). For
placebo, 24 h-corrected urine output increased from
12.0 ± 3.7 to 28.8 ± 12.8 mL kg−1 d−1 (P < 0.001). Twenty-
four hour urinary sodium excretion increased significantly
in all treatment groups. For placebo, 24 h sodium excre-
tion increased from 1.6 ± 0.3 to 2.7 ± 1.3 mmol kg−1 day−1
(P = 0.016, Fig. 1b). Urinary chloride excretion increased
with once daily robenacoxib (P = 0.025), twice daily robe-
nacoxib (P = 0.03) and ketoprofen (P = 0.03) but not with
placebo (P = 0.07) (Fig. 1c). Urinary 24 h potassium did
not significantly increase with any treatment (Fig. 1d).
Urinary calcium excretion significantly increased with
all treatments.
Haemoconcentration and GFR
Plasma creatinine increased from baseline with once
daily robenacoxib (143.1 vs 129.2 μmol L−1, 11 % in-
crease, P = 0.029), twice daily robenacoxib (150.0 vs
127.6 μmol L−1, 17 % increase, P < 0.001) and ketoprofen
(149.6 vs 133.3 μmol L−1, 12 % increase, P = 0.017) but
not with placebo (Fig. 2a). For means of all treatments,
there were numerically small but non-significant increases
in packed cell volume (43.4 ± 0.7 % vs 39.7 ± 1.0 %, Fig. 2b)
and plasma protein (69.1 ± 2.6 vs 66.7 ± 1.5 g L−1, Fig. 2c).
A significant decrease in GFR from baseline was obtained
only with ketoprofen (1.45 ± 0.25 vs 1.74 ± 0.38 mL kg−1
min−1, P < 0.01, Fig. 1f).
Effect on the renin angiotensin aldosterone system (RAAS)
Plasma renin activity (PRA) increased significantly
from baseline with placebo and once daily robenacoxib
but not with twice daily robenacoxib or ketoprofen
(Fig. 2d). The maximal placebo-associated PRA in-
crease was reduced by 18, 16 and 53 % with the three
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Fig. 2 (Short title) Biochemistry and Renin Angiotensin Aldosterone system. (Detailed legend) Plasma creatinine (a), packed cell volume (b)
plasma protein (c), plasma renin activity (d), plasma aldosterone (e) and daily urinary aldosterone excretion (f) at baseline (white columns) and
after administration of oral furosemide (2 mg kg−1 twice-daily, couloured columns) with either placebo (Plac.), robenacoxib 1 to 2 mg kg−1 once- Rob(1/
d) or twice-daily Rob(2/d), or ketoprofen once-daily (Keto, 1 mg kg−1). Data are presented as mean (SD) for seven healthy cats enrolled in the cross-
over study. Significant changes from baseline are notified as *P < 0.05, ** P < 0.01 and *** P < 0.001. Significant differences between treatment groups
are notified as # P < 0.05 and ## P < 0.01
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Fig. 1 (Short title) Daily urinary volume and electrolyte excretion. (Detailed legend) Daily urinary volume (a), sodium (b), chloride (c), potassium
(d), calcium (e) excretion and GFR determined by endogenous urinary creatinine excretion (f) at baseline (white columns) and after administration
of oral furosemide (2 mg kg−1 twice-daily, couloured columns) with either placebo (Plac.), robenacoxib 1 to 2 mg kg−1 once- Rob(1/d) or twice-
daily Rob(2/d), or ketoprofen once-daily (Keto, 1 mg kg−1). Data are presented as mean (SD) for 7 healthy cats enrolled in the crossover study.
Significant change from baseline are notified as * P < 0.05, ** P < 0.01 and *** P < 0.001
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drug treatments, respectively. The increase in PRA from
baseline was higher with placebo compared to ketoprofen
(10.5 ± 4.4 vs 4.9 ± 5.0 ng ml−1 h−1, P < 0.01).
Plasma aldosterone concentration did not increase sig-
nificantly from baseline with any treatment (Fig. 2e). How-
ever, inter-animal variability in differences between baseline
and post-treatment concentrations was high. In contrast,
urinary aldosterone excretion increased from baseline with
all treatments (P < 0.001 or P < 0.05, Fig. 2f). The increase
was greatest after placebo dosing and the magnitude of this
maximal response was attenuated by 75 % by ketoprofen
(P < 0.01) and 65 % by twice daily robenacoxib (P < 0.05).
Urinary eicosanoid excretion
The daily urinary excretion of PGE2 was significantly
decreased with all treatments; the relative response was
greater with ketoprofen (70 ± 6.1 %) compared to placebo
(27 ± 34.6 %, P < 0.05, Fig. 3a). PGE2 suppression was less
and non-significant compared to placebo for robenacoxib
groups (50 ± 23.0 and 47 ± 17.5 % for once and twice daily
dosing, respectively). The excretion of 6-keto-PGF1α was
unaffected with all treatments (Fig. 3c). Urinary TxB2 ex-
cretion increased significantly from baseline only with pla-
cebo (6.4 ± 2.8 vs 3.5 ± 1.5 ng kg−1 d−1, P < 0.021, Fig. 3b).
This increase with placebo was attenuated by 27, 41 and
41 % with once daily robenacoxib, twice daily robenacoxib
and ketoprofen, respectively.
Urinary protein and enzyme excretion
Daily urinary protein concentration and γ-glutamyl trans-
ferase activity were not increased by any treatment (Fig. 3d
and e). Mean urinary N-acetyl-beta-D-glucosaminidase
(NAG) activity for all treatments increased from baseline
(P = 0.003, Fig. 3f) and there were no significant differ-
ences between treatments.
Immunohistochemistry study
COX-1 expression in urinary tissues
For control tissues, strong diffuse COX-1 positive immu-
nostaining was seen in the cytoplasm and perinuclear
area in the muscle of normal feline bladders. All negative
control sections had no detectable immunostaining for
COX-1 and COX-2.
The median [interquartile range] COX-1 expression
scores of cats with normal kidneys are summarized in
Table 1. The strongest immunopositive staining was ob-
served in the thick and thin limbs of the loop of Henle
and the collecting duct (Fig. 4a to d). Moderate binding
of COX-1 occurred in the proximal tubule and MD.
COX-1 staining was slight (weak positive in some cats
and negative others) in the afferent arteriole and
A
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Fig. 3 (Short title) Daily urinary prostaglandin and enzyme excretion (activity). (Detailed legend) Daily urinary prostanoids excretion [PGE2 (a), TxB2
(b) and 6-ketoPGF1α (c)], daily proteinuria (d), gamma-Glutamyl transpeptidase (e) and N-acetyl-beta-D-glucosaminidase, NAG (f) urinary activities
at baseline (white columns) and after administration of oral furosemide (2 mg kg−1 twice-daily, couloured columns) with either placebo (Plac.), robenacoxib 1
to 2 mg kg−1 once- Rob(1/d) or twice-daily Rob(2/d), or ketoprofen once-daily (Keto, 1 mg kg−1). Data are presented as mean (SD) for seven healthy cats
enrolled in the crossover study. Significant change from baseline are notified as * P< 0.05 and *** P< 0.001. Significant differences between treatment
groups are notified as # P< 0.05
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glomeruli in normal kidneys. COX-1 expression was
undetectable in medullary interstitial cells. There was
no statistically significant difference in COX-1 intensity
scores between young and old cats.
COX-2 expression in renal tissue
Intense COX-2 positive immunostaining was seen con-
sistently in the juxtaglomerular apparatus (JGA) of posi-
tive control sections. The regional immunohistochemical
scores for COX-2 are summarised in Table 1. Positive
COX-2 staining was highest in the MD, the thin and
thick limb of the loop of Henle and the proximal tubule
(Fig. 4e to h). COX-2 expression was usually depression
was usually detectable in the glomeruli, the distal tubule
and the collecting duct but only some of the arterioles.
There were no statistically significant differences in
COX-2 intensity scores between young and old cats.
Discussion
This is the first study to report the acute renal effects of
COX-1 and COX-2 selective NSAIDs, administered at
clinically recommended doses in combination with fur-
osemide to healthy conscious cats.
Validation of the furosemide model
Furosemide (2 mg kg−1 twice daily; clinically relevant
dose) produced reliable diuretic and saluretic responses
and stimulated the RAAS (increased PRA and plasma al-
dosterone concentrations).
Non-selective and COX-2 selective NSAIDs cause so-
dium retention in healthy humans [10]. Moreover, non-
selective NSAIDs attenuate in vitro the furosemide-induced
reduction in loop chloride reabsorption [15]. They also
compete with furosemide for the organic acid transporter
in proximal tubular cells, limiting its access to NaK2Cl
transporters [16]. In the present study, there was no inhibi-
tory effect of acute NSAID administration on the diuretic
and saluretic actions of furosemide; therefore electrolyte
homeostasis in the cat may be regulated by mechanisms
over-riding the acute COX blockade.
Link between furosemide administration and increase in
PRA
There are two possible mechanisms to explain increased
renin activity in response to furosemide in the present
study [17]. First, by blocking NaK2Cl transporter, fur-
osemide removes the link between chloride concentration
in the MD and renin secretion. Consequently, the MD sig-
nal for renin secretion persists regardless of the amount
NaCl passing through the distal tubule [18], accounting
for the increase in PRA. In these circumstances, basolat-
eral cells of the MD of rabbit perfused kidneys increased
COX-2 and PGE2 synthase expression [19, 20]. The result-
ing PGE2 release constitutes the physiological mechanism
of signal transmission from MD cells to the JGA [19]. This
response regulates renin release and renal vascular resist-
ance. Using a similar experimental setting to the present
study, furosemide-induced renin release was blocked by
COX-2 inhibitors in humans [12]. Second, the later occur-
ring action of furosemide (due to the induced sodium and
water depletion) is to reduce stimulation of the afferent
arteriolar stretch receptors and carotid / aortic sinus baro-
receptors, thus stimulating renin release [12, 17].
Effects of NSAIDS on RAAS
Ketoprofen significantly attenuated the furosemide-
induced ten-fold increase in PRA in in this study, whereas
the effect of robenacoxib was equivocal and probably dose
dependent. An unavoidable limitation of the study is that
ketoprofen (at the clinical dose rate and route selected) in-
hibits not only COX-1 for 24 h, but also COX-2 for 10 to
11 h after oral administration (see integration of pharma-
cokinetic and pharmacodynamic data in Additional file 1:
S2). Hence, attenuation of the PRA response may be due
to inhibition of COX-1 or requires inhibition of both
Table 1 COX-1 and COX-2 scores in the kidney of normal
young and old cats
COX-1 immunostaining Young (n = 10) Old (n = 11)
Thick limb 1.37 [1.01–1.66] 1.75 [1.43–1.81]
Collecting duct 1.32 [0.98–1.82] 1.41 [1.25–1.66]
Distal tubule 1.10 [0.84–1.35] 1.14 [1.00–1.43]
Thin limb 0.97 [0.58–1.20] 1.42 [0.82–1.55]
Macula densa 0.75 [0.55–0.81] 0.82 [0.80–1.13]
Proximal tubule 0.56 [0.44–0.71] 0.74 [0.36–0.91]
Glomerulus 0.48 [0.09–1.01] 0.70 [0.15–1.00]
Arteriole 0.50 [0.28–0.80] 0.60 [0.40–0.70]
Medullary interstitial cell 0.00 [0.0–0.25] 0.00 [0.00–0.00]
COX-2 immunostaining Young (n = 10) Old (n = 11)
Macula densa 1.29 [0.71–2.18] 1.32 [1.00–2.03]
Thin limb 1.16 [0.65–1.64] 1.10 [0.75–1.64]
Thick limb 1.10 [0.77–1.19] 0.93 [0.75–1.16]
Proximal tubule 0.73 [0.41–0.85] 1.19 [0.72–1.30]
Medullary interstitial cell 1.00 [0.00–1.00] 1.00 [0.00–1.00]
Collecting duct 0.81 [0.38–1.12] 0.90 [0.60–1.01]
Distal tubule 0.45 [0.27–1.13] 0.86 [0.42–1.09]
Glomerulus 0.75 [0.31–1.41] 0.80 [0.65–2.00]
Arteriole 0.15 [0.00–2.23] 0.10 [0.00–0.30]
For each cat, an average intensity score for each structure was calculated as
described in the methods section (range 0 to 3). This single value has been
used to calculate the median [interquartile range] value presented in the table
for each group of cats. There was no difference in expression between young
and old cats for either isoenzyme (P > 0.05)
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isoforms. Inhibition of COX-2 alone was insufficient to
suppress this response. To elucidate the relative im-
portance of COX-1 and COX-2 in mediating the PRA
response to furosemide administration requires the use
of a highly selective COX-1 inhibitor; no such com-
pound is currently available.
Aldosterone release from the zona glomerulosa of the
adrenal cortex is controlled by angiotensin II in circum-
stances of renal hypo-perfusion and increase in plasma
potassium. Plasma potassium concentration did not
change significantly in this study (results not shown),
although the fractional excretion of potassium increased
Fig. 4 (Short title) Renal localization of COX-1 and COX-2: (Detailed legend) COX-1 (Fig. 4.a to d, 4 top panels) and COX-2 (Fig. 4.e to h, 4 bottom panels)
in the normal feline kidney. Results from 21 cats (ten young and 11 old). Magnification × 400. ⋆ denotes the macula densa, ⋆⋆ denotes the glomerulus,
+ denotes the afferent arteriole, # denotes the distal tubule, ## denotes the proximal tubule, * denotes the thin limb of the loop of Henle, ** denotes
the thick limb of the loop of Henle, *** denotes the collecting duct and denotes the medullary interstitial cells. a to d: The most intense expression
of COX-1 was found in the thick limb of the loop of Henle (c) followed by the collecting duct (d), the distal tubule (b), the thin limb of the loop of
Henle (c) and the macula densa (a), respectively. In the proximal tubule (b), the glomerulus (a) and the afferent arteriole (a), COX-1 expression was very
weak to absent. h: The strongest COX-2 expression was found in the macula densa (e) followed by the thin loop of Henle (g), the thick limb of the
loop of Henle (g), the proximal tubule (f), the medullary interstitial cells (g) and the collecting duct (h), respectively. In the distal tubule (f), the
glomerulus (e) and the afferent arteriole (e), COX-2 was either expressed very weakly or was absent
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with all treatments, commensurate with the decrease in
GFR. Plasma aldosterone concentration fluctuates over the
course of the day, as aldosterone release can be affected by
several factors, such as adrenocorticotropic hormone
(ACTH), body position, hyponatremia and atrial natri-
uretic peptide [21]. In the present study, the minor stress
associated with restraint and blood sampling could have
exerted an acute effect on ACTH and plasma aldosterone
concentrations. The high inter-animal variability could ac-
count for the lack of significance of the numerical increase
in plasma aldosterone after any of the treatment. Aldoster-
one excretion in urine collected over 24 h is, therefore,
likely to provide a better indication of time-averaged al-
dosterone release than spot plasma aldosterone concen-
tration measurement. Urinary aldosterone response was
suppressed by both ketoprofen and twice daily robena-
coxib and to a lesser extent by once daily robenacoxib.
This supports a role for COX-2 but suggests that COX-1
is also involved in aldosterone secretion, as ketoprofen
inhibited urinary aldosterone more than either dose of
robenacoxib. Furthermore, the urinary aldosterone data
are consistent with the PRA data, supporting the view that
inhibition of both COX-1 and COX-2 is required to block
the effect of furosemide in activating RAAS.
Immunochemistry evidence for COX-1 and 2 in
furosemide-induced PRA response
Evidence for COX-2, and potentially also for COX-1, in-
volvement in signalling from the MD cells to the renin
secreting cells of the JGA, was obtained by immunohis-
tochemistry, which demonstrated high level expression
of COX-2 and weak expression of COX-1 within the
MD of both young and older adult cats. In other species,
the use of immunohistochemistry to localise COX-isoforms
has demonstrated species and age-related differences in ex-
pression. Only COX-2 has been localised to the MD in
most species, including dogs, rabbits and rats [7, 22, 23],
but with both isoforms identified in mice [24]. Distribution
of the isoenzymes in the other compartments of the fe-
line kidney is similar to that seen in rodents, rabbits
and dogs [7, 22, 23, 25]. In humans, COX-2 expression is
reported in the MD in the foetus [26] and in subjects over
50 years of age [9], hence the inclusion of two age groups
of cats in the present study. Kidney tissue was obtained
from cats undergoing post-mortem examination for rea-
sons other than CKD. These cats cannot, therefore, be
described as healthy, and other features of their disease
process might have altered renal tissue COX-enzyme
expression. Nevertheless, the data indicate that COX-2 is
the principal isoform present in cells of the feline MD,
whilst the finding of weak expression of COX-1 at this
location suggests that interaction between the two iso-
forms may generate the signal to the JGA cells from the
MD to secrete renin in some cats. This interpretation of
the immunohistochemistry data is strengthened by the re-
sults of the functional studies which suggest involvement
of both COX isoenzymes in signalling from MD to JGA to
stimulate renin secretion.
Vascular effects of furosemide and NSAIDs
In the placebo group, the significant increase in plasma cre-
atinine and slight but non-significant increases in packed
cell volume and total protein suggest contraction of the vol-
ume of the central compartment by furosemide [27]. This
may have led to reduced tonic stimulation of either the
stretch receptors of the afferent arteriole or the cardiac or
arterial baroreceptors, leading to release of renin, angioten-
sin II and aldosterone. However, systolic arterial blood pres-
sure was not measured and therefore a baroreceptor
mechanism cannot be confirmed. Altered stretch of afferent
arteriole wall activates RAAS and the release of angiotensin
II and aldosterone, leading to increased sodium reabsorp-
tion. Offset of the vasoconstrictive action of angiotensin II
on the afferent arteriole and preservation of GFR is
dependent on the local release of prostaglandins [4, 28].
GFR was significantly decreased with ketoprofen and
approached significance for robenacoxib (both doses); it is
therefore possible that the COX-1 dependent RAAS
response to volume depletion was blunted with ketoprofen,
accounting for the lesser effect of robenacoxib on
furosemide-induced PRA increase.
Effects of furosemide and NSAIDs on urinary eicosanoids
Urinary eicosanoid excretion derives from local renal pro-
duction. The effect of furosemide on urinary PGE2 excre-
tion varies with species. It was unchanged in humans [12]
but increased in dogs [29]. Surprisingly, in the present
study furosemide reduced PGE2 excretion, probably
through inhibition of PGE2 production. Against this back-
ground, it was not possible to relate PGE2 inhibition by
NSAIDs to their action on furosemide-induced renin
secretion. However, ketoprofen further reduced urinary
PGE2 excretion, possibly indicating that renal COX-1 is
the major source of urinary PGE2 in the cat. Attenuation
of the furosemide increased urinary TxB2 excretion by
ketoprofen and twice daily robenacoxib, compared to pla-
cebo, indicates that furosemide-induced renal TxB2 syn-
thesis is probably the consequence of a COX-2 mediated
compensatory vasoconstrictive mechanism.
Effects of furosemide and NSAIDs on urinary protein
excretion
In dogs, increase in NAG index is associated with renal
proximal tubular necrosis [30]. Furosemide significantly
increased urinary NAG activity in all groups in the present
study and the increases were not exacerbated by concomi-
tant NSAID treatment. For all cats, NAG returned to
baseline levels during the intervals between periods,
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indicating either a transient nephrotoxic effect of furosem-
ide or, more likely, an increased lysosomal turnover in re-
sponse to the increase in tubular fluid flow [31, 32].
Methods
In vivo study design
Seven neutered experimental cats (four males, three
females, 2 years old), weighing 3.7 ± 0.34 kg, were enrolled
in a four period crossover study. They were group housed
except during sampling periods when they were individu-
ally housed in cages equipped with a timed urine collec-
tion system previously validated in cats [33]. Each cat was
fed 25 g of a low sodium dry food twice daily (RF23, Royal
Canin, Aimargues, France). Drinking water was available
ad libitum. The study complied with the EU Directive
2010/63/EU (Project License Number 70/6132) and
the protocol was approved by the Royal Veterinary
College Ethics and Welfare Committee. All cats were
declared healthy at the end of the study and subse-
quently re-homed.
At the beginning of each period, a pooled baseline urine
sample was collected over 48 h during days 1, 2 and 3
(Fig. 5). A baseline blood sample (cephalic or jugular vene-
puncture) was collected in the middle of the urinary col-
lection interval (between 10.30 and 11.45 am on day 2).
The treatments comprised administration of furosemide
2 mg/kg (Furosemide, Milpledge, Retfort, UK) orally twice
daily (08.00 am, 07.00 pm) from the morning of day 6 to
the morning of day 8, concomitantly with one of four
NSAID/placebo dosing regimens (Fig. 5): (1) robenacoxib
(Onsior, 6 mg flavoured tablets, Novartis Animal Health,
Camberley, UK,1 to 2 mg kg−1) once daily; (2) robenacoxib
(1 to 2 mg kg−1) twice daily; (3) ketoprofen once daily
(Ketofen, 5 mg tablets, Merial, Harlow, UK, 1 mg kg−1);
and (4) placebo once daily (active ingredient excluded).
Robenacoxib tablets composition was 6.25 % (6 mg) active
ingredient, 30.0 % microcryst. cellulose Avicel PH 101,
3.0 % polyvinylpyrrolidone Kollidon K30, 43.75 % yeast,
3.0 % Crospovidone Kollidon CL, 12.0 % yeast, 0.5 % van-
illa, 1.0 % colloidal silicon dioxide (Aerosil 200), 0.5 % mag-
nesium stearate, makes a total weight of 96.0 mg per tablet.
Furosemide, NSAIDs or placebo tablets were inserted
in a small cube of moist cat food to facilitate oral admin-
istration. The rest of meal was withheld until at least
90 min after drug administration. Treatment order was
randomised, following a Latin square design.
Further urine collection commenced after the first fur-
osemide treatment and lasted for 48 h during days 6, 7
and 8. Blood was collected on the morning of day 7
(from 10.30 to 11.45 am, 2 to 3 h after the morning
treatment) in the same animal ranking order as day 2. A
10 day washout interval was allowed between the last
administration of furosemide and collection of the base-
line blood sample in the next period.
Blood sampling, processing and assays
Packed cell volume was measured before sample centrifu-
gation (10 min, 1500 x g, 20 °C) and storage of plasma ali-
quots at −80 °C until analysis. Plasma renin activity
(Gamma Coat®, CA1553, DiaSorin Ltd, Bracknell, UK) was
measured by radioimmunoassay, as validated by Syme et
al. [34]. A radioimmunoassay validated in cats [30] was
Treatment
(furosemide 
and NSAID)
Day 1 Day 2 Day 3 Day 6Day 4+5 Day 7 Day 8
Baseline collection
Individual urine collection
every 12h
for 48 h total
Urine refrigerated for 
max 48h, proportional 
pooling of collection 
fractions and aliquoting
Individual urine collection
every 12h
for 48 h total
Blood sample
Furosemide and NSAIDs
Immediate analysis or storage at -80°C
Urine refrigerated for 
max 48h, proportional 
pooling of collection 
fractions and aliquoting
Fig. 5 (Short title) Sampling schedule (one period of the study), including baseline and the treatment timescale. (Detailed legend) A previously
validated collection system was used for urine collection on Day 1 to Day 3 and Day 6 to Day 8 [33]. The system recorded accurately the time
urination occurred. Oral furosemide (2 mg kg−1) was administered twice-daily from the morning of day 6 to the morning of day 8. The treatment
consisted of administering furosemide with one of four oral NSAID/placebo dosing regimens (placebo, 1 to 2 mg kg−1 robenacoxib once-daily, 1
to 2 mg kg−1 robenacoxib twice-daily and ketoprofen 1 mg kg−1 once-daily) from the morning of day 6 to the morning of day 8
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used to measured plasma aldosterone concentration
(Coat-a-Count®, Siemens Medical Solutions Diagnostics,
Los Angeles, CA, USA). Creatinine (Jaffé colorimetric
method), protein, sodium, potassium, chloride and calcium
(ILAB 600, Idexx, Warrington, UK) concentrations were
measured at a commercial laboratory.
Urine sampling, processing and assays
Urine was collected twice daily (08.00 am, 07.00 pm).
Urinary specific gravity as recorded for each sample. Urine
collected during the first day was stored at 4 °C for 24 h
and pooled with urine from the second day. Accurate
urination times and volumes were recorded to calculate
24 h averaged urinary volumes and analyte excretions over
the collection period [33]. The 24 h urine excretion was
corrected by the average percentage of voided volume lost
through retention in the litter tray [33] and used alongside
plasma and urinary creatinine concentrations to calculate
GFR by endogenous urinary creatinine clearance. A non-
selective COX inhibitor (ibuprofen 10 μM, Ref I7378,
Sigma-Aldrich Co. Ltd, Poole, UK) solubilised in methanol
was added to collected urine (1:1000 v/v) to prevent ex
vivo eicosanoid production. Urine was centrifuged (1000
g, 20 °C, 10 min) and the supernatant stored at −80 °C.
Urinary electrolytes (sodium, chloride, potassium, cal-
cium) were measured using ion sensitive electrodes and
creatinine and protein concentrations were measured
using Jaffé and Lowry methods, respectively (ILab 600
analyser, Idexx). Urinary aldosterone concentration was
measured by RIA after liquid extraction with dichloro-
methane. Urinary prostanoids were co-extracted on re-
verse phase extraction columns (Varian SepPak 200 mg
C18 LRC, Agilent) following a protocol adjusted from the
manufacturer’s recommendation. Urinary TxB2 concentra-
tion was measured by RIA (TxB2 antibody, Ref P7291,
Sigma and TxB2 Tracers, GE Healthcare biosciences Ltd,
Little Chalfont, UK) and urinary PGE2 and 6-keto-PGF2α
were measured by enzymatic immunoassay (Immunoas-
says ADI-900-001 and ADI-900-004, Assay Designs, MI,
USA). Urinary activity of γ-glutamyl transferase was mea-
sured on fresh samples within 24 h after the last collection
using a colorimetric method (γ-GT, Randox, Crumlin,
UK). Urinary NAG was measured with a commercially
available colorimetric assay (N-acetyl-β-glucosaminidase
kit, no. 875406, Roche, Basel, Switzerland), validated in
the cat [31]. Details of all assay protocols and validation
results for blood and urine samples are presented in the
Additional file 2: S1.
Post-mortem study and specimen provenance
Post-mortem kidney specimens were obtained (with in-
formed owner consent) from 10 young (<5 years) and
11 old (>9 years) client-owned cats with normal renal
function that had been euthanized or had died of nat-
ural non-renal causes. None of the cats had clinical
signs indicative of chronic kidney disease (CKD), such
as urinary specific gravity <1.035 or plasma creatin-
ine >177 μmol L−1.
Immunohistochemistry protocols
Three micrometre thick paraffin sections were dewaxed
and rehydrated in grading ethanol followed by heating
slides in a microwave at medium-high power in citrate
buffer pH 6.0 for 15 min. Endogenous peroxidase activity
was blocked by treating the tissue section with 3 % hydro-
gen peroxide for 10 min. Subsequently, 1.5 % normal goat
serum (Vector Laboratories, Burlingame, CA) or 1.5 %
normal donkey serum (Santa Cruz Biotechnology, Dallas,
TX) was applied to block non-specific background stain-
ing of COX-1 and COX-2 primary antibodies, respectively.
Slides were incubated with COX-1 (160108, Cayman
Chemical, Camdridge, UK) or COX-2 (sc-1745, Santa
Cruz Biotechnology) primary antibodies at 1:100 dilution
at room temperature for 2 h and were then treated with
biotinylated secondary antibody for COX-1 (BA-1000,
Vector Laboratories) or COX-2 (sc-2023, Santa Cruz Bio-
technology) for 1 h. Immunoactive complexes were de-
tected by incubating the sections with avidin-biotin
complex system (Santa Cruz Biotechnology) for 30 min
and visualized with diaminobenzidine. The sections
were counterstained with hematoxylin. Negative con-
trol slides were prepared by replacing the primary anti-
body with 1.5 % normal serum. Feline normal bladder
sections were used as the COX-1 positive control [35],
while canine foetal kidney sections were selected as the
COX-2 positive control [36]. Stained sections were
evaluated microscopically in a blinded manner and
standard morphological criteria were used to identify
the kidney structures. For each renal structure, staining
intensity was assessed from 0 to 3. In each cat, 10 MD,
10 tubules and 20 glomeruli were randomly assessed
and the median [interquartile range] intensity score was
calculated as previously described [37].
Statistical analysis
SAS software (Version 9.1.3, SAS Institute, Cary, NC,
USA) was used for statistical analysis. When necessary,
data were log transformed to satisfy the assumption of
normal distribution of the residuals (Shapiro Wilk test)
and homoscedasticity. An ANOVA model, containing se-
quence, period, sex, and baseline value as fixed effects and
animal as a random effect, was fitted to all dependent vari-
ables. The effects of NSAID treatments were compared in
a pairwise manner. The reported p-values are raw p-
values corrected with a Tukey adjustment for multiple
comparisons. In addition, the difference from baseline
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(or logarithmic equivalent) after furosemide for each
NSAID treatment was tested against zero using a paired
Student’s t-test. Results are presented as mean ± SD and
P < 0.05 was considered significant. For immunostaining
studies, the Kruskal-Wallis test was used to compare the
intensity scores between groups with significance level set
at P < 0.05.
Conclusions
The present study indicates the lack of effect of acute
COX inhibition on furosemide-induced diuresis and
natriuresis in cats. It is suggested both COX-1 and
COX-2 are involved in the PRA and aldosterone re-
sponse to furosemide and that COX-2 may be involved
in regulating pathways other than angiotensin II stimu-
lated aldosterone secretion. These findings, supported by
the immunohistochemical localisation of COX-1 in the
MD of the feline kidney, illustrate that renal physiology
is species-dependent.
Additional files
Additional file 1 S1: PK-PD integration of robenacoxib and
ketoprofen (description of data): estimation of the average duration
of COX-1 and COX-2 inhibition achieved with robenacoxib once a
day (RSID), robenacoxib twice a day (RBID) and ketoprofen (KET)
using data from the literature. (DOCX 424 KB)
Additional file 2 S2: analytical method description and validation:
(description of data) Validation data for Plasma Renin Activity,
plasma and urinary aldosterone, urinary prostanoids and urinary
enzymes. (DOCX 22 kb)
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